Comment
doi: 10.1016/S1470-2045(11)70194-2.
Epub 2011 Jul 23.
Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?
Affiliations
- PMID: 21783418
- DOI: 10.1016/S1470-2045(11)70194-2
Item in Clipboard
Comment
Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?
Lancet Oncol.
2011 Aug.
No abstract available
Comment in
-
Pharmacokinetics of gefitinib and erlotinib.Lancet Oncol. 2011 Nov;12(12):1093. doi: 10.1016/S1470-2045(11)70306-0. Lancet Oncol. 2011. PMID: 22041538 No abstract available.
Comment on
-
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.Lancet Oncol. 2011 Aug;12(8):735-42. doi: 10.1016/S1470-2045(11)70184-X. Epub 2011 Jul 23. Lancet Oncol. 2011. PMID: 21783417 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
